Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Oesophago-gastric Cancer × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 66 Stomach Neoplasms 8 Triple Negative Breast Neoplasms 7 Carcinoma, Hepatocellular 6 Inflammatory Breast Neoplasms 5 Non-Muscle Invasive Bladder Neoplasms 3 Primary Breast Cancer 2 Pathologic Complete Response 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Ductal, Breast 2 Urinary Bladder Neoplasms 1 Sarcoma 1 Rhabdomyosarcoma 1 Resectable HER2-positive Breast Cancer 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Oesophago-gastric Cancer 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, Large B-Cell, Diffuse 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 HER2 Positive Early Breast Cancer 1 Gallbladder Neoplasms 1 Fallopian Tube Neoplasms 1 Epstein-Barr Virus Infections 1 Endometrial Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms, Male 1

Interventions

Panitumumab 1 Oxaliplatin 1 Epirubicin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00824785 2012-12-11

REAL3

Royal Marsden NHS Foundation Trust

Phase 3 Terminated

Gastrointestinal

Oesophago-gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡